U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 6 of 6 results

Status:
US Approved Rx (2019)
First approved in 2001

Class (Stereo):
CHEMICAL (ABSOLUTE)



Pimecrolimus, an ascomycin macrolactam derivative, is an inhibitor of T-cell and mast-cell activation, developed and launched by Novartis for the potential treatment of psoriasis and allergic, irritant and atopic dermatitis. The topical formulation h...
Status:
US Approved Rx (2025)
First approved in 1994

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tacrolimus, previously known as FK506, is the active ingredient in Prograf. Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506...
Status:
US Approved Rx (2024)
First approved in 1983

Class (Stereo):
CHEMICAL (ABSOLUTE)



Cyclosporins are cyclic polypeptide macrolides that were originally derived from the soil fungus Tolypocladium inflatum. Cyclosporine (also known as cyclosporine A) was discovered by Sandoz and developed for the tretment of immune disorders. The drug...
Status:
US Approved Rx (2001)
First approved in 2001

Class:
PROTEIN

structurally diverse
Status:
US Approved Rx (1996)
First approved in 1981

Class:
STRUCTURALLY DIVERSE

Status:
US Approved Rx (2025)
First approved in 1994

Class (Stereo):
CHEMICAL (ABSOLUTE)



Tacrolimus, previously known as FK506, is the active ingredient in Prograf. Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506...